

**REMARKS**

Applicant has canceled claims 1 and 3, and provided new claims 17 and 18.

Applicant has amended claims 2, 13-14.

Applicant has amended withdrawn claims 4-8 so that their recited dependences reflect the canceling of withdrawn claim 3 and submission of new claim 18. Furthermore, new claim 18 is hereby withdrawn from consideration. Withdrawn process claims 4-8 and 18 have been amended so as to be compliant with the rejoinder requirements found in 37 C.F.R. §1.104, should the pending product claims be allowable.

The subject matter of new claims 17 and 18 are based upon canceled claims 1 and 3. New claims 17 and 18 share the same essential disclosure of canceled claims 1 and 3; however there are technical and substantive differences between the new and cancelled claims. Specifically, new claims 17 and 18 have been amended to replace the commas, which separate the chemical formula elements found in canceled claims 1 and 3, with semi-colons. Furthermore, Applicant has added additional punctuation where necessary.

New claims 17 and 18 have additional substantive disclosures not found in canceled claims 1 and 3. New claims 17 and 18 point out that the groups, optionally substituted by one or more substituents, are hetrocyclic. This disclosed element can be found at line 12 of the second (2) full paragraph of new claim 17 and new claim 18. Support for this disclosure can be found at paragraph 9, line 1 of the pending application. Furthermore, new claims 17 and 18 also point out that linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl groups could be bonded to the same N atom to jointly represent a C<sub>2</sub>-C<sub>5</sub> alkylene group. This can be found at the eighth (8) full paragraph of new claim 17 and claim 18. Support for this disclosure can be found at paragraphs 33 and 16 of the pending application. New claims 17 and 18 also define that in formula element T, the groups optionally substituted are aryl and heterocyclic. This can be found in the twentieth (20) full paragraph of new claims 17 and 18. Support can be found at paragraph 29 of the pending application.

None of the submitted new claims constitute new matter.

Amended claim 2 no longer points out the term "isomeric." Additionally, amended claim 2 has been made dependent on new claim 17.

Amended claims 13 and 14 no longer disclose "active principal". Furthermore, amended claim 13 no longer references "isomer" in its disclosure.

The Examiner has rejected claims 1-2 and 13-16 under 35 U.S.C. §112, second paragraph, as failing to particularly point out and distinctly claim patentable subject matter. Specifically, the Examiner points out that the variable elements provided in claim 1 are unclear, and fail to point to specific subject matter.

Applicant respectfully submits that the presently submitted new claim 17 renders the Examiner's rejection moot. New claim 17 clearly defines the variables found within the claim.

The Examiner has rejected claims 13 and 14 under 35 U.S.C. §112, second paragraph, as being indefinite. Specifically, the Examiner cites the usage of the term "active principle" as indefinite.

Applicant respectfully submits that presently submitted amended claims 13 and 14 render the Examiner's rejection moot. "Active principal" is not disclosed in either claim 13 or 14.

The Examiner has rejected claims 2, 13 and 14 under 35 U.S.C. §112, first paragraph, for lack of enablement. Specifically, the Examiner submits that the specification does not reasonably provide enablement for "isomers" in the claimed compound.

Applicant respectfully submits that presently submitted amended claims 2, 13 and 14 render Examiner's rejection moot. References to "isomers" and "isomeric forms" are not present in the disclosure of the amended claims.

Respectfully submitted,



James V. Costigan

Registration No. 25,669

**MAILING ADDRESS**

Hedman & Costigan, P.C.  
1185 Avenue of the Americas  
New York, N.Y. 10036-2646  
(212) 302-8989